Mark Roback
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Conscious Sedation | 22 | 2025 | 84 | 4.020 |
Why?
| Emergency Service, Hospital | 30 | 2021 | 1978 | 2.170 |
Why?
| Ketamine | 17 | 2021 | 85 | 2.010 |
Why?
| Hypnotics and Sedatives | 13 | 2025 | 159 | 1.950 |
Why?
| Anesthesia | 3 | 2022 | 130 | 1.400 |
Why?
| Laryngismus | 3 | 2022 | 6 | 0.940 |
Why?
| Autism Spectrum Disorder | 3 | 2025 | 375 | 0.800 |
Why?
| Laryngoscopy | 2 | 2019 | 100 | 0.800 |
Why?
| Anesthesiology | 2 | 2024 | 45 | 0.790 |
Why?
| Anesthetics, Dissociative | 9 | 2021 | 28 | 0.750 |
Why?
| Intubation, Intratracheal | 2 | 2019 | 241 | 0.730 |
Why?
| Analgesia | 5 | 2018 | 93 | 0.720 |
Why?
| Airway Management | 1 | 2019 | 43 | 0.620 |
Why?
| Emergency Medical Services | 3 | 2021 | 562 | 0.600 |
Why?
| Intubation, Gastrointestinal | 1 | 2017 | 76 | 0.550 |
Why?
| Child, Preschool | 30 | 2025 | 10462 | 0.550 |
Why?
| Child | 40 | 2025 | 20860 | 0.530 |
Why?
| Gastrostomy | 1 | 2017 | 113 | 0.520 |
Why?
| Liability, Legal | 1 | 2016 | 39 | 0.520 |
Why?
| Gastric Bypass | 1 | 2017 | 106 | 0.510 |
Why?
| Anti-Allergic Agents | 1 | 2016 | 50 | 0.510 |
Why?
| Fasting | 4 | 2019 | 265 | 0.500 |
Why?
| Infant | 27 | 2021 | 8997 | 0.460 |
Why?
| Patient Transfer | 1 | 2016 | 162 | 0.450 |
Why?
| Emergency Treatment | 4 | 2021 | 116 | 0.420 |
Why?
| Hospitalization | 4 | 2017 | 2080 | 0.420 |
Why?
| Hypersensitivity | 1 | 2016 | 277 | 0.400 |
Why?
| Vomiting | 6 | 2020 | 129 | 0.330 |
Why?
| Atropine | 2 | 2010 | 26 | 0.320 |
Why?
| Pediatrics | 5 | 2015 | 1061 | 0.310 |
Why?
| Adolescent | 26 | 2025 | 20241 | 0.300 |
Why?
| Humans | 55 | 2025 | 129078 | 0.290 |
Why?
| Midazolam | 4 | 2018 | 50 | 0.270 |
Why?
| Propofol | 2 | 2017 | 55 | 0.260 |
Why?
| Consensus | 5 | 2024 | 646 | 0.260 |
Why?
| Anesthetics, Intravenous | 2 | 2017 | 39 | 0.240 |
Why?
| Premedication | 1 | 2004 | 40 | 0.230 |
Why?
| Etomidate | 2 | 2016 | 6 | 0.230 |
Why?
| Credentialing | 1 | 2024 | 18 | 0.230 |
Why?
| Male | 29 | 2025 | 63248 | 0.230 |
Why?
| Bradycardia | 1 | 2004 | 56 | 0.220 |
Why?
| Emergency Medicine | 2 | 2004 | 227 | 0.220 |
Why?
| Intussusception | 1 | 2003 | 28 | 0.220 |
Why?
| Enema | 1 | 2003 | 43 | 0.220 |
Why?
| Orthopedic Procedures | 1 | 2006 | 228 | 0.210 |
Why?
| Terminology as Topic | 2 | 2017 | 204 | 0.200 |
Why?
| Prospective Studies | 10 | 2021 | 7070 | 0.200 |
Why?
| Administration, Intravenous | 3 | 2018 | 140 | 0.200 |
Why?
| Retrospective Studies | 14 | 2025 | 14562 | 0.190 |
Why?
| Respiratory Tract Diseases | 2 | 2005 | 151 | 0.190 |
Why?
| Infant, Newborn | 9 | 2021 | 5707 | 0.190 |
Why?
| Female | 25 | 2025 | 68274 | 0.180 |
Why?
| Excitatory Amino Acid Antagonists | 2 | 2018 | 95 | 0.180 |
Why?
| Hospitals, Pediatric | 5 | 2021 | 518 | 0.180 |
Why?
| Comorbidity | 2 | 2025 | 1542 | 0.180 |
Why?
| Government Regulation | 1 | 2020 | 50 | 0.170 |
Why?
| Epiglottitis | 1 | 2000 | 4 | 0.170 |
Why?
| Preoperative Care | 2 | 2020 | 343 | 0.170 |
Why?
| Fasciitis, Necrotizing | 1 | 2000 | 15 | 0.170 |
Why?
| Administration, Intranasal | 2 | 2018 | 84 | 0.170 |
Why?
| Racepinephrine | 1 | 2019 | 1 | 0.160 |
Why?
| Infant Mortality | 1 | 2000 | 97 | 0.160 |
Why?
| Croup | 1 | 2019 | 27 | 0.160 |
Why?
| Chickenpox | 1 | 2000 | 100 | 0.150 |
Why?
| Depressive Disorder, Treatment-Resistant | 1 | 2018 | 5 | 0.150 |
Why?
| Oral and Maxillofacial Surgeons | 1 | 2018 | 1 | 0.150 |
Why?
| Endpoint Determination | 1 | 2018 | 76 | 0.150 |
Why?
| Meningococcal Infections | 1 | 1998 | 23 | 0.150 |
Why?
| Protein C | 1 | 1998 | 45 | 0.140 |
Why?
| Deep Sedation | 1 | 2017 | 12 | 0.140 |
Why?
| Patient Outcome Assessment | 1 | 2018 | 128 | 0.140 |
Why?
| Bronchodilator Agents | 1 | 2019 | 252 | 0.140 |
Why?
| Respiratory Sounds | 1 | 1998 | 121 | 0.140 |
Why?
| Reference Standards | 1 | 2017 | 169 | 0.140 |
Why?
| Radiography, Thoracic | 1 | 1998 | 162 | 0.140 |
Why?
| Clinical Competence | 1 | 2024 | 1021 | 0.140 |
Why?
| Ranitidine | 1 | 2016 | 14 | 0.130 |
Why?
| Checklist | 1 | 2017 | 99 | 0.130 |
Why?
| Diphenhydramine | 1 | 2016 | 31 | 0.130 |
Why?
| Hematocele | 1 | 1996 | 1 | 0.130 |
Why?
| Cohort Studies | 6 | 2020 | 5400 | 0.130 |
Why?
| Splenic Rupture | 1 | 1996 | 4 | 0.130 |
Why?
| Methylprednisolone | 1 | 2016 | 83 | 0.130 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 576 | 0.130 |
Why?
| Nitrous Oxide | 1 | 2016 | 22 | 0.130 |
Why?
| Advisory Committees | 1 | 2017 | 231 | 0.130 |
Why?
| Patient Safety | 2 | 2018 | 293 | 0.130 |
Why?
| Scrotum | 1 | 1996 | 26 | 0.130 |
Why?
| Dexmedetomidine | 1 | 2016 | 45 | 0.120 |
Why?
| Bronchiolitis | 1 | 1997 | 92 | 0.120 |
Why?
| Shock, Septic | 1 | 1998 | 204 | 0.120 |
Why?
| Anxiety | 1 | 2022 | 947 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 2 | 2018 | 1974 | 0.120 |
Why?
| Diabetic Ketoacidosis | 3 | 2002 | 195 | 0.120 |
Why?
| Feasibility Studies | 1 | 2019 | 860 | 0.120 |
Why?
| Edema | 1 | 1996 | 127 | 0.120 |
Why?
| Epinephrine | 1 | 2016 | 180 | 0.120 |
Why?
| Research Design | 2 | 2018 | 1039 | 0.120 |
Why?
| Standard of Care | 1 | 2015 | 70 | 0.120 |
Why?
| Respiration, Artificial | 1 | 2019 | 594 | 0.120 |
Why?
| Risk Factors | 11 | 2021 | 9804 | 0.120 |
Why?
| Research | 1 | 2017 | 413 | 0.110 |
Why?
| Double-Blind Method | 3 | 2016 | 1864 | 0.110 |
Why?
| Canada | 4 | 2018 | 355 | 0.110 |
Why?
| Blood | 1 | 1994 | 99 | 0.110 |
Why?
| Haemophilus influenzae | 1 | 1994 | 63 | 0.110 |
Why?
| Child Behavior Disorders | 1 | 2015 | 133 | 0.110 |
Why?
| Practice Guidelines as Topic | 4 | 2019 | 1526 | 0.110 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 1005 | 0.110 |
Why?
| Spleen | 1 | 1996 | 518 | 0.110 |
Why?
| Wounds and Injuries | 1 | 2000 | 719 | 0.100 |
Why?
| Streptococcus pneumoniae | 1 | 1994 | 157 | 0.100 |
Why?
| Treatment Outcome | 5 | 2019 | 10256 | 0.100 |
Why?
| Wounds, Nonpenetrating | 1 | 1996 | 283 | 0.100 |
Why?
| Patient-Centered Care | 1 | 2017 | 504 | 0.100 |
Why?
| Bacteremia | 1 | 1994 | 190 | 0.100 |
Why?
| Oxygen | 1 | 1997 | 913 | 0.100 |
Why?
| Analgesics, Opioid | 1 | 2020 | 915 | 0.100 |
Why?
| Analgesics | 2 | 2005 | 165 | 0.100 |
Why?
| United States | 4 | 2021 | 13992 | 0.090 |
Why?
| Brain Edema | 2 | 2002 | 61 | 0.090 |
Why?
| Patient Readmission | 1 | 1997 | 674 | 0.090 |
Why?
| Reproducibility of Results | 1 | 2019 | 3047 | 0.090 |
Why?
| Infusions, Intravenous | 3 | 2009 | 395 | 0.090 |
Why?
| Delphi Technique | 2 | 2024 | 220 | 0.090 |
Why?
| Clinical Protocols | 2 | 2015 | 256 | 0.090 |
Why?
| Anesthesia Recovery Period | 2 | 2009 | 12 | 0.090 |
Why?
| Incidence | 7 | 2017 | 2635 | 0.090 |
Why?
| Patient Discharge | 1 | 1997 | 858 | 0.090 |
Why?
| Glycopyrrolate | 1 | 2010 | 3 | 0.090 |
Why?
| Adjuvants, Anesthesia | 1 | 2010 | 10 | 0.090 |
Why?
| Muscarinic Antagonists | 1 | 2010 | 27 | 0.080 |
Why?
| Otorhinolaryngologic Diseases | 1 | 2009 | 14 | 0.080 |
Why?
| Injections, Intramuscular | 2 | 2009 | 127 | 0.080 |
Why?
| Neck Pain | 1 | 2009 | 26 | 0.080 |
Why?
| Neck Injuries | 1 | 2009 | 20 | 0.080 |
Why?
| Fentanyl | 2 | 2012 | 79 | 0.080 |
Why?
| Quality Improvement | 1 | 2017 | 1103 | 0.080 |
Why?
| Adult | 6 | 2019 | 35423 | 0.080 |
Why?
| Time Factors | 4 | 2020 | 6579 | 0.080 |
Why?
| Psychomotor Agitation | 1 | 2009 | 65 | 0.080 |
Why?
| Ondansetron | 1 | 2008 | 14 | 0.080 |
Why?
| Antiemetics | 1 | 2008 | 39 | 0.070 |
Why?
| Respiratory System | 1 | 2009 | 153 | 0.070 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2015 | 828 | 0.070 |
Why?
| Age Factors | 5 | 2021 | 3137 | 0.060 |
Why?
| Postoperative Complications | 1 | 2017 | 2497 | 0.060 |
Why?
| Logistic Models | 5 | 2016 | 1966 | 0.060 |
Why?
| Foeniculum | 1 | 2005 | 1 | 0.060 |
Why?
| Plant Poisoning | 1 | 2005 | 9 | 0.060 |
Why?
| Methemoglobinemia | 1 | 2005 | 13 | 0.060 |
Why?
| Colorado | 3 | 2005 | 4445 | 0.060 |
Why?
| Infusions, Parenteral | 1 | 2005 | 39 | 0.060 |
Why?
| Guideline Adherence | 2 | 2019 | 528 | 0.060 |
Why?
| Reflex | 1 | 2004 | 67 | 0.060 |
Why?
| Chi-Square Distribution | 3 | 2010 | 513 | 0.060 |
Why?
| Respiration Disorders | 1 | 2004 | 73 | 0.060 |
Why?
| Competency-Based Education | 1 | 2024 | 70 | 0.060 |
Why?
| Respiratory Aspiration | 2 | 2018 | 32 | 0.050 |
Why?
| Drug Therapy, Combination | 1 | 2005 | 1020 | 0.050 |
Why?
| Hypocapnia | 1 | 2001 | 10 | 0.050 |
Why?
| Injections, Intravenous | 2 | 2013 | 200 | 0.050 |
Why?
| Blood Urea Nitrogen | 1 | 2001 | 53 | 0.050 |
Why?
| Recurrence | 1 | 2003 | 1013 | 0.040 |
Why?
| Infant Equipment | 1 | 2000 | 8 | 0.040 |
Why?
| Fever | 1 | 2021 | 301 | 0.040 |
Why?
| Respiratory Aspiration of Gastric Contents | 1 | 2019 | 1 | 0.040 |
Why?
| Corneal Diseases | 1 | 2000 | 34 | 0.040 |
Why?
| Streptococcus pyogenes | 1 | 2000 | 35 | 0.040 |
Why?
| Transportation of Patients | 1 | 2000 | 50 | 0.040 |
Why?
| Eye Injuries | 1 | 2000 | 44 | 0.040 |
Why?
| Risk Assessment | 3 | 2018 | 3290 | 0.040 |
Why?
| United States Food and Drug Administration | 1 | 2020 | 204 | 0.040 |
Why?
| Case-Control Studies | 3 | 2010 | 3336 | 0.040 |
Why?
| Cholinergic Antagonists | 2 | 2009 | 29 | 0.040 |
Why?
| American Dental Association | 1 | 2018 | 7 | 0.040 |
Why?
| Prothrombin | 1 | 1998 | 23 | 0.040 |
Why?
| Length of Stay | 1 | 2003 | 1128 | 0.040 |
Why?
| Benzodiazepines | 2 | 2009 | 132 | 0.040 |
Why?
| Anesthesiologists | 1 | 2018 | 12 | 0.040 |
Why?
| Survival | 1 | 1998 | 39 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2009 | 1968 | 0.040 |
Why?
| Platelet Count | 1 | 1998 | 83 | 0.040 |
Why?
| Hematocrit | 1 | 1998 | 93 | 0.040 |
Why?
| Radiology, Interventional | 1 | 2018 | 31 | 0.040 |
Why?
| Triage | 1 | 2000 | 214 | 0.040 |
Why?
| Resuscitation | 1 | 2000 | 244 | 0.040 |
Why?
| Acute Disease | 2 | 2002 | 978 | 0.040 |
Why?
| Hypoglycemia | 1 | 2002 | 427 | 0.040 |
Why?
| Hypoxia | 1 | 2004 | 1071 | 0.030 |
Why?
| Diabetes Mellitus, Type 1 | 3 | 2002 | 3604 | 0.030 |
Why?
| Leukocyte Count | 1 | 1998 | 328 | 0.030 |
Why?
| Fibrinogen | 1 | 1998 | 159 | 0.030 |
Why?
| Physical Examination | 1 | 2018 | 238 | 0.030 |
Why?
| Sensitivity and Specificity | 2 | 2000 | 1842 | 0.030 |
Why?
| Hospitals, General | 1 | 2016 | 22 | 0.030 |
Why?
| Endotoxins | 1 | 1998 | 221 | 0.030 |
Why?
| Multivariate Analysis | 3 | 2010 | 1504 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2020 | 676 | 0.030 |
Why?
| Rabbits | 1 | 1998 | 757 | 0.030 |
Why?
| Psychiatric Status Rating Scales | 1 | 2018 | 527 | 0.030 |
Why?
| Diagnostic Errors | 1 | 1997 | 163 | 0.030 |
Why?
| Staphylococcus aureus | 1 | 2000 | 429 | 0.030 |
Why?
| Hemoglobins | 1 | 1998 | 344 | 0.030 |
Why?
| Trauma Severity Indices | 1 | 1996 | 109 | 0.030 |
Why?
| Societies, Medical | 1 | 2019 | 760 | 0.030 |
Why?
| Remission Induction | 1 | 2015 | 269 | 0.030 |
Why?
| Spectrophotometry | 1 | 1994 | 58 | 0.030 |
Why?
| Heart Diseases | 1 | 1998 | 356 | 0.030 |
Why?
| Odds Ratio | 1 | 2017 | 1021 | 0.030 |
Why?
| Thrombosis | 1 | 1998 | 331 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2005 | 2016 | 0.030 |
Why?
| Heart Arrest | 1 | 2016 | 327 | 0.030 |
Why?
| Algorithms | 1 | 2019 | 1626 | 0.020 |
Why?
| Databases, Factual | 1 | 2017 | 1289 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 1996 | 1435 | 0.020 |
Why?
| Young Adult | 2 | 2017 | 12310 | 0.020 |
Why?
| Postoperative Nausea and Vomiting | 1 | 2010 | 11 | 0.020 |
Why?
| Switzerland | 1 | 2009 | 35 | 0.020 |
Why?
| Pain | 1 | 2015 | 761 | 0.020 |
Why?
| Adverse Drug Reaction Reporting Systems | 1 | 2008 | 74 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 5036 | 0.020 |
Why?
| Disease Models, Animal | 1 | 1998 | 3999 | 0.020 |
Why?
| Registries | 1 | 2015 | 1916 | 0.020 |
Why?
| Fractures, Bone | 1 | 2012 | 416 | 0.020 |
Why?
| Documentation | 1 | 2008 | 184 | 0.020 |
Why?
| Contraindications | 1 | 2006 | 90 | 0.020 |
Why?
| Methylene Blue | 1 | 2005 | 24 | 0.020 |
Why?
| Cyanosis | 1 | 2005 | 16 | 0.020 |
Why?
| Foodborne Diseases | 1 | 2005 | 48 | 0.010 |
Why?
| Enzyme Inhibitors | 1 | 2005 | 829 | 0.010 |
Why?
| Bicarbonates | 1 | 2001 | 43 | 0.010 |
Why?
| Random Allocation | 1 | 2001 | 352 | 0.010 |
Why?
| Confidence Intervals | 1 | 2000 | 318 | 0.010 |
Why?
| Survival Analysis | 1 | 2002 | 1283 | 0.010 |
Why?
| Fluorescein Angiography | 1 | 2000 | 139 | 0.010 |
Why?
| Drug Interactions | 1 | 2000 | 370 | 0.010 |
Why?
| Reference Values | 1 | 2000 | 791 | 0.010 |
Why?
| Carbon Dioxide | 1 | 2001 | 261 | 0.010 |
Why?
| Socioeconomic Factors | 1 | 2002 | 1192 | 0.010 |
Why?
| Visual Acuity | 1 | 2000 | 319 | 0.010 |
Why?
| Sex Factors | 1 | 2002 | 1950 | 0.010 |
Why?
| Animals | 1 | 1998 | 34708 | 0.010 |
Why?
| Mental Disorders | 1 | 2002 | 1026 | 0.010 |
Why?
|
|
Roback's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|